After an average of 18-36 months under androgen suppression therapy by surgical castration, LHRH, and steroidal or non-steroidal antiandrogens, almost all patients with metastatic prostate cancer show PSA progression as a sign of androgen-independent but still androgen-sensitive tumor growth. Our understanding and the treatment of such castration-resistant prostate cancer has changed markedly. The introduction of new drugs like abiraterone and MDV3100 has shown that prostate cancer progression even in the " hormonerefractory" stage is driven by androgen receptor signaling. Based on this information the question of whether androgen deprivation therapy in castration-resistant prostate cancer should be continued or not is still of relevance. This review gives a critical overview of the literature and current guideline recommendations. © Springer-Verlag 2012.
CITATION STYLE
Spahn, M., & Krebs, M. (2012, January). Wie soll die hormontherapie beim kastrationsresistenten prostatakarzinom fortgeführt werden? Urologe - Ausgabe A. https://doi.org/10.1007/s00120-011-2738-9
Mendeley helps you to discover research relevant for your work.